CN115916168A - 大麻二酚在治疗癫痫中的用途 - Google Patents

大麻二酚在治疗癫痫中的用途 Download PDF

Info

Publication number
CN115916168A
CN115916168A CN202180042463.2A CN202180042463A CN115916168A CN 115916168 A CN115916168 A CN 115916168A CN 202180042463 A CN202180042463 A CN 202180042463A CN 115916168 A CN115916168 A CN 115916168A
Authority
CN
China
Prior art keywords
cbd
caffeine
cannabidiol
day
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042463.2A
Other languages
English (en)
Chinese (zh)
Inventor
李洁
凯文·詹姆斯·克雷格
丹尼尔·亚当·切基茨
大卫·约翰·克里奇利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiwei Research Co ltd
Original Assignee
Jiwei Research Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiwei Research Co ltd filed Critical Jiwei Research Co ltd
Publication of CN115916168A publication Critical patent/CN115916168A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180042463.2A 2020-06-18 2021-06-16 大麻二酚在治疗癫痫中的用途 Pending CN115916168A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2009321.7A GB202009321D0 (en) 2020-06-18 2020-06-18 Use of cannabinoids in the treatment of epilepsy
GB2009321.7 2020-06-18
PCT/GB2021/051520 WO2021255446A1 (en) 2020-06-18 2021-06-16 Use of cannabidiol in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
CN115916168A true CN115916168A (zh) 2023-04-04

Family

ID=71838306

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042463.2A Pending CN115916168A (zh) 2020-06-18 2021-06-16 大麻二酚在治疗癫痫中的用途

Country Status (11)

Country Link
US (1) US20230225986A1 (https=)
EP (1) EP4167980B1 (https=)
JP (1) JP2023530500A (https=)
KR (1) KR20230026337A (https=)
CN (1) CN115916168A (https=)
AU (1) AU2021291128A1 (https=)
CA (1) CA3181694A1 (https=)
GB (2) GB202009321D0 (https=)
MX (1) MX2022016038A (https=)
TW (1) TW202214217A (https=)
WO (1) WO2021255446A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
AU2024300440A1 (en) * 2023-07-25 2026-03-12 Algorae Pharmaceuticals Ltd Compositions and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203239A1 (en) * 2015-06-17 2016-12-22 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US20170172941A1 (en) * 2014-10-14 2017-06-22 Gw Pharma Limited Use of Cannabinoids in the Treatment of Epilepsy
WO2019097238A1 (en) * 2017-11-15 2019-05-23 GW Research Limited Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
CN109985042A (zh) * 2017-12-29 2019-07-09 汉义生物科技（北京）有限公司 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015308546A1 (en) * 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
US20180360771A1 (en) * 2017-06-14 2018-12-20 Yury Leon Shmerlis Cannabidiol chewing gum
US20200172841A1 (en) * 2018-12-04 2020-06-04 Donald F. Wilkes Alcohol-free wine beverage

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170172941A1 (en) * 2014-10-14 2017-06-22 Gw Pharma Limited Use of Cannabinoids in the Treatment of Epilepsy
WO2016203239A1 (en) * 2015-06-17 2016-12-22 GW Research Limited Use of cannabinoids in the treatment of epilepsy
WO2019097238A1 (en) * 2017-11-15 2019-05-23 GW Research Limited Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome
CN109985042A (zh) * 2017-12-29 2019-07-09 汉义生物科技（北京）有限公司 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMANTA, D.: ""Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy"", 《PEDIATRIC NEUROLOGY》, vol. 96, 22 March 2019 (2019-03-22), pages 24 - 29, XP085706546, DOI: 10.1016/j.pediatrneurol.2019.03.014 *

Also Published As

Publication number Publication date
EP4167980A1 (en) 2023-04-26
AU2021291128A1 (en) 2022-12-01
CA3181694A1 (en) 2021-12-23
KR20230026337A (ko) 2023-02-24
GB202009321D0 (en) 2020-08-05
TW202214217A (zh) 2022-04-16
WO2021255446A1 (en) 2021-12-23
MX2022016038A (es) 2023-02-02
GB202108690D0 (en) 2021-08-04
US20230225986A1 (en) 2023-07-20
GB2598187A (en) 2022-02-23
JP2023530500A (ja) 2023-07-18
EP4167980B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
Lipton et al. Caffeine in the management of patients with headache
Fabiano et al. Paediatric pharmacology: remember the excipients
TW202139980A (zh) 以大麻二酚及依維莫司(everolimus)治療結節性硬化症之方法
US10525093B2 (en) Cannabinoid formulations and method of making the same
US11925645B2 (en) Enhanced caffeinated beverage composition
KR102727062B1 (ko) 중수소화 카페인 및 그의 용도
CN115916168A (zh) 大麻二酚在治疗癫痫中的用途
JP2002097136A (ja) 喫煙欲求抑制組成物
KR20200010211A (ko) Pde9 저해제를 포함하는 약제학적 조성물
JP6585060B2 (ja) ピリドキサミン化合物及びチアミン化合物を組み合わせてなる医薬組成物
KR20220163384A (ko) 칸나비스 사용 장애를 치료하고 칸나비노이드 금단을 완화하기 위한 방법 및 조성물
KR20090007281A (ko) 소양증 및 염증을 억제·완화하기 위한 의약 및 기능성 식품
JP5527900B2 (ja) アスパラチン様ジヒドロカルコン、未発酵ルイボスからの抽出物およびその調製方法
CN115279197A (zh) 增强型含咖啡因饮料组合物
KR102531387B1 (ko) 홍경천 및 연자육을 포함하는 수면 장애 개선용 조성물
US11439603B2 (en) Compositions for ameliorating, preventing or treating somnipathy including phloroglucinol as active ingredient and compositions for suppressing intolerance to or alleviating side effects of agonist at benzodiazepine binding site of GABA-A receptor including phloroglucinol as active ingredient
KR101864384B1 (ko) 콜린 알포세레이트를 유효성분으로 하는 쥐남의 치료, 개선 또는 예방용 조성물 및 방법
EP2942056A1 (en) Novel uses of licochalcone a
AU2018324768A1 (en) Composition for decreasing serum uric acid level
AU2018101586A4 (en) Uses of polydatin
JPH06340542A (ja) 薬用植物由来の骨疾患の予防・治療剤
JP7637357B2 (ja) 血管保護のためのターメリックオイルを含有する組成物、ならびにこのような組成物を含む飲食品および香料
Abdelkawy et al. Pharmacokinetics interaction of dapoxetine with different doses of green tea extract in male healthy volunteers using midazolam as CYP3A4 enzyme probe
CN111093670A (zh) 基于特咖宁的补充剂及其与咖啡因协同组合中的使用方法
KR102673520B1 (ko) 육계 추출물을 유효성분으로 포함하는 스타틴계 화합물에 의해 유도된 pcsk9 억제용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Britain

Address after: Sheffield, Kent, UK

Applicant after: Jazz Pharmaceutical Research UK Ltd.

Address before: Cambridge County, England

Applicant before: Jiwei Research Co.,Ltd.

Country or region before: Britain

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230404